Tandem Wins FDA Clearance On First Stand-Alone Glycemic Controller

Tandem Diabetes Care received FDA clearance for its Control-IQ technology for use with Tandem's t:slim X2 insulin pump and Dexcom's G6 continuous glucose monitoring system, making it the first hybrid closed-loop system to deliver automatic correction boluses and adjust background insulin levels to help prevent high and low blood sugars.

T slim
Tandem's t:slim X2 insulin pump with Control-IQ technology is the first stand-alone insulin delivery device to win clearance from the US FDA. • Source: Courtesy Tandem Diabetes Care

An automated insulin delivery system that landed marketing authorization from the US Food and Drug Administration on 13 December represents a breakthrough for patients with type 1 diabetes.

Tandem Diabetes Care Inc.'s Control IQ is an automated insulin delivery system that combines the t:slim X2 insulin pump,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diabetic Care

More from Device Area